Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial

European Journal of Preventive Cardiology

Volumn 22, Issue 4, 2015, Pages 519-526

  Horne, Benjamin D ^a,b   Anderson, Jeffrey L ^a,b   Muhlestein, Joseph B ^a,b   Ridker, Paul M ^c   Paynter, Nina P ^c  

^a Intermountain Heart Institute   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CBC; clinical decision rule; clinical prediction rule; red cell distribution width

Indexed keywords

AGED; ARTICLE; BLOOD CELL COUNT; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPLETE BLOOD COUNT RISK SCORE; DISEASE ASSOCIATION; ERYTHROCYTE FUNCTION AND CHARACTERISTICS; ERYTHROCYTE PARAMETERS; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED CELL DISTRIBUTION WIDTH; RISK ASSESSMENT; SECONDARY ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DYSLIPIDEMIAS; KAPLAN MEIER METHOD; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME; TREATMENT OUTCOME;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

AGED; BLOOD CELL COUNT; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; DYSLIPIDEMIAS; ERYTHROCYTE INDICES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; ROSUVASTATIN CALCIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924988191     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313519347     Document Type: Article

References (23)

1. Anderson JL, Ronnow BS, Horne BD, et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol. 2007 ; 99: 169-174
2. Horne BD, Anderson JL, John JM, et al. Which white blood cell compartments predict increased cardiovascular risk?. J Am Coll Cardiol. 2005 ; 45: 1638-1643
3. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005 ; 91: 181-184
4. Forhecz Z, Gombos T, Borgulya G, et al. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009 ; 158: 659-666
5. Azab B, Torbey E, Hatoum H, et al. Usefulness of red cell distribution width in predicting all-cause longterm mortality after non-ST-elevation myocardial infarction. Cardiology. 2011 ; 119: 72-80
6. Horne BD, May HT, Kfoury AG, et al. The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail. 2010 ; 12: 1203-1213
7. Horne BD, May HT, Muhlestein JB, et al. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med. 2009 ; 122: 550-558
8. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207
9. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003 ; 108: 2292-2297
10. Ridker PM, Fonseca FA, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007 ; 100: 1659-1664
11. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol. 2009 ; 54: 1209-1222
12. Müller-Riemenschneider F, Holmberg C, Rieckmann N, et al. Barriers to routine risk-score use for healthy primary care patients. Arch Intern Med. 2010 ; 170: 719-724
13. Grady D, Berkowitz SA. Why is a good clinical prediction rule so hard to find?. Arch Intern Med. 2011 ; 171: 1701-1702
14. Tokgozoglu L, Bruckert E. Implementation, target population, compliance and barriers to risk guided therapy. Eur J Prev Cardiol. 2012 ; 19 (S2). 37-41
15. Horne BD. The red cell distribution width: What is its value for risk prognostication and for understanding disease pathophysiology?. Cardiology. 2011 ; 119: 140-141
16. Patel KV, Ferrucci L, Ershler WB, et al. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med. 2009 ; 169: 515-523
17. Braun E, Domany E, Kenig Y, et al. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit Care. 2011 ; 15: R194 - R202
18. Oh HJ, Park JT, Kim JK, et al. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant. 2012 ; 27: 589-594
19. Majercik S, Fox J, Knight S, et al. Red cell distribution width is predictive of mortality in trauma patients. J Trauma Acute Care Surg. 2013 ; 74: 1021-1026
20. Horne BD, Hegewald M, Muhlestein JB, et al. The red cell distribution width strongly predicts mortality among patients evaluated by pulmonary function testing. Chest. 2012 ; 142: 667A - 667A
21. Morris AH Principles and practice of intensive care monitoring. Tobin MJ, ed. New York: McGraw-Hill ; 1997: 1355-1381.
22. Horne BD, Knight S, May HT. Panoptic total cardiovascular risk prediction using all possible predictors versus clinically optimized risk assessment using variable subsets: A review. Future Cardiol. 2012 ; 8: 765-778
23. Cui J, Forbes A, Kirby A, et al. Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study. Eur J Cardiovasc Prev Rehab. 2009 ; 16: 660-668